Work

Phase I study of the PARP inhibitor ABT-888 (veliparib) and pegylated liposomal doxorubicin (PLD) in recurrent ovarian (ov) and breast (br) cancers

Year: 2012

Type: article

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2011.12.053

Authors: B. Pothuri, J. Sparano, S. Blank, J. Curtin, E. Chuang, D. Hershman, A. Tiersten, L. Liebes, A. Chen, F. Muggia

Institutions: New York University, Albert Einstein College of Medicine, Montefiore Medical Center, NewYork–Presbyterian Hospital, Columbia University, National Cancer Institute

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1985146915

FWCI: 0.142

Cites:

Cited by: 1

Related to: 10